Adverse events noted with the use of second-generation ALK inhibitors as treatment for stage IV ALK-positive non–small cell lung cancer and strategies for appropriately monitoring and managing patients. WATCH VIDEO

Targeted Oncology

Authors: Dr. Stephen Liu

Read More